Figures computed from official regulatory filings — .
Analysttarget 34.83 USD (+671%) · consensus 5/5 · 6 buy · 0 hold · 0 sell
Ownershipinsiders 1.08% · institutions 64.7% · short 5.2% of float
In USD · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Adicet Bio, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
Market information source · Oct 19, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 19, 2026
Open-market timeline · full history
30 buys79 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Klickstein Lloyd | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Klickstein Lloyd | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Schor Chentrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Aftab Blake | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Peng Katie | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Grissinger Michael | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Sinclair Andrewtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Chodakewitz Jeffrey | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| DUBIN STEVEtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| RA CAPITAL MANAGEMENT, LLCtrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| RA CAPITAL MANAGEMENT, LLCtrack record | Other | n/a (No price was disclosed in the filing) | SEC |
| RA CAPITAL MANAGEMENT, LLCtrack record | Buy | $535.5K | conv 31 | SEC |
| RA CAPITAL MANAGEMENT, LLCtrack record | Buy | $525K | conv 33 | SEC |
| RA CAPITAL MANAGEMENT, LLCtrack record | Buy | $543.4K | conv 31 | SEC |
| ORBIMED ADVISORS LLCtrack record | Sell | $15.3K | SEC |
| ORBIMED ADVISORS LLCtrack record | Sell | $263.5K | SEC |
| ORBIMED ADVISORS LLCtrack record | Sell | $204.6K | SEC |
| ORBIMED ADVISORS LLCtrack record | Sell | $191.5K | SEC |
| Aftab Blake | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Harvey Brian Nicholas | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Maltzman Julia D. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Healey Don | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Schor Chentrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Harvey Brian Nicholas | Other | $4.6K | SEC |
| Healey Don | Other | $4.5K | SEC |